| Literature DB >> 35493894 |
Ni P Ariantari1,2, Elena Ancheeva1, Marian Frank1, Fabian Stuhldreier3, Dieter Meier1, Yvonne Gröner1, Irene Reimche4, Nicole Teusch4, Sebastian Wesselborg3, Werner E G Müller5, Rainer Kalscheuer1, Zhen Liu1, Peter Proksch1,6.
Abstract
Didymellanosine (1), the first analogue of the decahydrofluorene-class of natural products bearing a 13-membered macrocyclic alkaloid conjugated with adenosine, and a new benzolactone derivative, ascolactone C (4) along with eight known compounds (2, 3, 5-10), were isolated from a solid rice fermentation of the endophytic fungus Didymella sp. IEA-3B.1 derived from the host plant Terminalia catappa. In addition, ascochitamine (11) was obtained when (NH4)2SO4 was added to rice medium and is reported here for the first time as a natural product. Didymellanosine (1) displayed strong activity against the murine lymphoma cell line L5178Y, Burkitt's lymphoma B cells (Ramos) and adult lymphoblastic leukemia T cells (Jurkat J16), with IC50 values of 2.0, 3.3 and 4.4 µM, respectively. When subjected to a NFκB inhibition assay, didymellanosine (1) moderately blocked NFκB activation in the triple-negative breast cancer cell line MDA-MB 231. In an antimicrobial assay, ascomylactam C (3) was the most active compound when tested against a panel of Gram-positive bacteria including drug-resistant strains with MICs of 3.1-6.3 µM, while 1 revealed weaker activity. Interestingly, both compounds were also found active against Gram-negative Acinetobacter baumannii with MICs of 3.1 µM, in the presence of a sublethal concentration (0.1 µM) of colistin. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35493894 PMCID: PMC9049863 DOI: 10.1039/c9ra10685e
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Compounds isolated from Didymella sp. IEA-3B.1.
1H and 13C NMR data for compound 1a
| No. |
|
| No. |
|
|
|---|---|---|---|---|---|
| 1 | 43.5, CH | 2.68, q (7.1) | 27 | 85.7, C | |
| 2 | 138.0, C | 28 | 46.0, CH2 | 2.94, d (12.5); 2.88, d (12.5) | |
| 3 | 131.3, CH | 4.44, s | 29 | 128.9, C | |
| 4 | 52.6, C | 30 | 130.6, CH | 7.10, d (8.4) | |
| 5 | 144.7, C | 31 | 119.4, CH | 6.97, dd (8.4, 2.2) | |
| 6 | 125.5, C | 32 | 157.3, C | ||
| 7 | 46.9, CH | 1.95, t (12.0) | 33 | 122.0, CH | 6.71, dd (8.4, 2.2) |
| 8 | 42.7, CH | 1.54, m | 34 | 129.9, CH | 7.11, d (8.4) |
| 9 | 39.6, CH2 | 2.08, d (12.2); 0.72, m | 35 | 7.70, s | |
| 10 | 31.8, CH | 1.52, m | 36 | 7.46, d (5.1) | |
| 11 | 44.7, CH2 | 1.74, m; 0.68, m | 37 | 152.2, C | |
| 12 | 30.9, CH | 1.79, m | 39 | 150.8, CH | 8.20, s |
| 13 | 56.3, CH | 1.16, m | 41 | 147.8, C | |
| 14 | 87.0, CH | 4.52, dd (8.1, 5.2) | 43 | 140.4, CH | 8.47, s |
| 15 | 52.3, CH | 1.97, m | 45 | 119.8, C | |
| 16 | 46.2, CH | 3.49, d (7.2) | 46 | 87.9, CH | 5.89, d (5.2) |
| 17 | 163.6, C | 47 | 73.7, CH | 4.48, q (5.4) | |
| 18 | 106.6, C | 48 | 70.0, CH | 4.13, q (4.6) | |
| 19 | 169.6, C | 49 | 85.3, CH | 3.94, q (3.9) | |
| 20 | 18.4, CH3 | 0.80, d (7.1) | 50 | 61.1, CH2 | 3.68, ddd (12.0, 4.7, 4.2); 3.52, ddd (12.0, 6.3, 3.8) |
| 21 | 12.3, CH3 | 0.40, s | 17-OH | 11.44, s | |
| 22 | 27.6, CH3 | 0.95, s | 27-OH | 6.62, s | |
| 23 | 15.3, CH3 | 1.73, s | 47-OH | 5.47, d (6.0) | |
| 24 | 22.4, CH3 | 0.92, d (6.5) | 48-OH | 5.18, d (5.1) | |
| 25 | 19.9, CH3 | 1.07, d (6.1) | 50-OH | 5.16, t (5.5) | |
| 26 | 55.5, CH | 4.11, d (5.1) |
Recorded at 600 MHz (1H) and 125 MHz (13C) in DMSO-d6.
Fig. 2COSY and key HMBC correlations of compound 1.
Fig. 3Key NOE correlations of compound 1.
1H and 13C NMR data for compound 4a
| Position |
|
|
|---|---|---|
| 1 | 90.7, C | |
| 3 | 160.7, C | |
| 3a | 102.8, C | |
| 4 | 156.2, C | |
| 5 | 112.7, C | |
| 6 | 163.7, C | |
| 7 | 101.3, CH | 6.58, s |
| 7a | 149.0, C | |
| 8 | 210.8, C | |
| 9 | 42.2, CH | 2.83, m |
| 10 | 26.6, CH2 | 1.71, ddd (14.0, 7.4, 6.7) |
| 1.36, ddd (14.0, 7.4, 6.7) | ||
| 11 | 11.7, CH3 | 0.87, t (7.4) |
| 12 | 16.7, CH3 | 0.79, d (6.8) |
| 13 | 23.4, CH3 | 1.67, s |
| 14 | 7.7, CH3 | 2.09, s |
Recorded at 600 MHz (1H) and 150 MHz (13C).
Data were extracted from HSQC and HMBC.
Fig. 4COSY and key HMBC correlations of compound 4.
Cell viability assay (IC50 in µM) of 1 towards L5178Y, Ramos, Jurkat J16 and MRC5 cells
| L5178Y | Ramos | Jurkat J16 | MRC5 | |
|---|---|---|---|---|
| 1 | 2.0 | 3.3 (6.4) | 4.4 (4.8) | 21.2 |
Kahalalide F (IC50 4.3 µM) as positive control.
Staurosporine (IC50 2.5 µM) as positive control.
Kahalalide F (IC50 10.3 µM) as positive control.
Selectivity index (SI): IC50 value against MRC5 cells divided by IC50 values against cancer cells.
Antibacterial activity (MIC in µM) of compounds 1–3 and 6
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|
| H37Rv | ATCC 29213 | ATCC 700699 | ATCC 29212 | ATCC 51299 | ATCC 35667 | ATCC 700221 | BAA 1605 | |
| 1 | >100 | 6.3 | 6.3 | 6.3 | 12.5 | 12.5 | 6.3 | 3.1 |
| 2 | >100 | 25 | 12.5 | 100 | 50 | 25 | 12.5 | 12.5 |
| 3 | >100 | 3.1 | 3.1 | 6.3 | 3.1 | 6.3 | 3.1 | 3.1 |
| 6 | >100 | 50 | 50 | >100 | >100 | 50 | >100 | >100 |
Rifampicin as positive control.
Moxifloxacin as positive control.
Drug-susceptible strain.
Methicillin-resistant strain of S. aureus (MRSA).
Vancomycin-resistant strain of E. faecalis.
Vancomycin-resistant strain of E. faecium.
Tested in the presence of a sublethal concentration (0.1 µM) of colistin.